Skip to Content
77 Mass Ave

Drugs on demand

A new technique makes it possible to rapidly make biopharmaceuticals in small batches.
December 19, 2018
Photo of pill bottles
Photo of pill bottlesJoshua Coleman | Unsplash

Biopharmaceuticals, a class of drugs comprising proteins such as antibodies and hormones, are often used to treat cancer, cardiovascular disease, and autoimmune disorders, and they’re increasingly important for precision medicine—drugs tailored to the genetic or molecular profiles of particular groups of patients.

Such drugs are normally manufactured at large facilities dedicated to a single product, using processes that are difficult to reconfigure. This rigidity means that manufacturers tend to focus on drugs needed by many patients, while drugs that could help smaller populations may not be made.

To help make more of these drugs available, MIT researchers have developed a new way to rapidly manufacture biopharmaceuticals on demand.

“Traditional biomanufacturing relies on unique processes for each new molecule that is produced,” says chemical engineering professor J. Christopher Love, who led the research team. “We’ve demonstrated a single hardware configuration that can produce different recombinant proteins in a fully automated, hands-free manner.”

The new, agile manufacturing system, which can fit on a lab benchtop, can easily be reprogrammed to rapidly produce a variety of different drugs on demand. It requires very little human oversight while maintaining the high quality of protein required for use in patients. The researchers have used it to produce three different biopharmaceuticals and showed that they are of comparable quality to commercially available versions.

Keep Reading

Most Popular

Large language models can do jaw-dropping things. But nobody knows exactly why.

And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.

OpenAI teases an amazing new generative video model called Sora

The firm is sharing Sora with a small group of safety testers but the rest of us will have to wait to learn more.

Google’s Gemini is now in everything. Here’s how you can try it out.

Gmail, Docs, and more will now come with Gemini baked in. But Europeans will have to wait before they can download the app.

This baby with a head camera helped teach an AI how kids learn language

A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.